NYT: A modest proposal to end the corruption debate

John Tierney at the New York Times writes that the fierce debate over the corrupting influence of corporate money in scientific research has become a fetish that is pushing some of the country's top researchers to stop accepting any support from drug companies. To rebalance the scales, he suggests that scientists simply detail all public and private donors on their Web pages and let journalists sort through them, leaving it to readers to decide if there is a conflict. Report

Suggested Articles

Compass' CD137 agonist cleared large tumors in mice that other I-O agents had failed to treat. It's advancing the drug into phase 1 human trials.

UPMC researchers are planning clinical trials of a COVID-19 vaccine that uses pieces of the virus' spike protein to create immunity.

Treating mice with niacin increased the number of immune cells in glioblastomas, reducing tumor size and extending survival.